Israeli PolyPid Signs $320 Million Drug Deal for US, Canada

Israeli pharmaceutical company PolyPid has signed a $320 million deal to sell its D-PLEX100 drug, designed to prevent surgical infections, in the United States and Canada.

21 Jul, 15:35 — 21 Jul, 15:35

Post Share

Sources

Showing 1 of 1 sources

jerusalem-postMostly Factual3d ago

Israeli PolyPid signs $320 million deal to sell drug preventing surgical infections in US, Canada

D-PLEX100 is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent abdominal surgical site infections.

Read full article →

PERSPECTA

PERSPECTA

Israeli PolyPid Signs $320 Million Drug Deal for US, Canada

Sources

Israeli PolyPid signs $320 million deal to sell drug preventing surgical infections in US, Canada

Related Stories

Pangasinan Fisherfolk Receive BFAR Livelihood Aid

Oriental Mindoro Power Cooperative Defends High Rates Amid Probe

Senator Lacson Uncovers More Evidence in Taguig Projects Investigation

Significant Spike Expected in Diesel and Gasoline Prices

PERSPECTA